AI in Genomics Market to Witness $6.22 Billion Growth by 2029


According to this latest publication from Meticulous Research®, the global AI in genomics market is slated to register a CAGR of 42.8% during the forecast period 2022–2029 to reach $6.22 billion by 2029

.

Unlocking the Potential of AI in Genomics

Introduction: AI’s Expanding Influence on Genomics

The application of artificial intelligence (AI) in genomics is one of the most promising technological advancements in the healthcare and biotechnology sectors. According to the research report "Artificial Intelligence in Genomics Market by Offering (Software, Services), Functionality (Sequencing, Gene Editing), Application (Diagnostics, Precision Medicine, Drug Discovery and Development), Delivery Mode (On-premises, Cloud) and End User—Global Forecast to 2029," AI is expected to dominate the genomics market, with a projected value of $6.22 billion by 2029, growing at a CAGR of 42.8%. Several factors are driving this growth, including AI’s potential to streamline the drug discovery process, accelerate diagnostics, and enhance personalized medicine through faster and more accurate genomic analyses.

Download Sample Copy Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5345 

Market Breakdown: Understanding the Segments

The global AI in genomics market is divided into several key segments, including offerings (software and services), functionality (genome sequencing and gene editing), applications (drug discovery, precision medicine, diagnostics), and delivery models (cloud and on-premises). This segmentation allows for a deeper analysis of how AI interacts with various aspects of genomics, offering insights into where investments are being made and which segments present the greatest opportunities for growth. In addition, a thorough competitive analysis helps to identify key market players, both regionally and globally, who are shaping the future of AI in genomics.

Software and Cloud Solutions: Catalysts of Growth

The software segment remains the largest in the AI in genomics market, particularly driven by subscription models and SaaS offerings. Software solutions provide consistent revenue streams, as they are often based on licensing or subscription models. Furthermore, the rapid pace of AI development in genomics ensures that software offerings continue to evolve, creating substantial growth opportunities. Cloud-based solutions, in particular, are gaining traction due to their scalability and cost-effectiveness. By adopting cloud technologies, pharmaceutical companies are able to manage large genomic datasets efficiently, improve collaboration across research teams, and provide secure access to data in real-time.

AI in Genome Sequencing: A Core Functionality

Genome sequencing is one of the most critical functionalities where AI is making a significant impact. AI is able to process vast amounts of genetic data, identify gene mutations, and uncover complex patterns more efficiently than traditional methods. This ability to analyze large datasets has expedited the discovery of disease-causing genes and accelerated the development of targeted therapies. Genome sequencing powered by AI is not only improving disease diagnosis but is also a key factor driving market growth in genomics.

AI in Drug Discovery: A Game-Changer in Pharmaceutical Development

The application of AI in drug discovery and development is revolutionizing the pharmaceutical industry. AI models are increasingly being used to predict the effectiveness of drug candidates, optimize molecular structures, and reduce the time spent on drug trials. AI-driven genomic analysis is speeding up the process of identifying therapeutic targets, thus reducing the time and cost associated with drug development. With the increasing shift towards precision medicine, AI’s role in drug discovery will continue to grow as companies seek to develop more effective and personalized treatments.

Driving Forces: Pharmaceutical and Biopharmaceutical Companies

Pharmaceutical and biopharmaceutical companies are the primary drivers of demand for AI in genomics. These companies are using AI to enhance the drug discovery process, reduce the time to market for new therapies, and develop more targeted treatments. AI allows for quicker identification of disease biomarkers and accelerates the development of personalized treatments, giving companies a competitive edge in the market. As the healthcare industry continues to embrace data-driven solutions, AI in genomics will play an increasingly vital role in shaping the future of medicine.

Regional Analysis: North America Leads the Charge

North America, particularly the United States, is the dominant region in the AI in genomics market. The country’s strong investments in both AI and genomics research, as well as its cutting-edge healthcare infrastructure, make it a leader in this field. Europe, with its strong healthcare systems and commitment to AI in healthcare, is also a key player in the market. Meanwhile, the Asia-Pacific region is emerging as a major market, driven by technological advancements and increasing healthcare investments in countries like China and Japan.

Conclusion: Transforming Healthcare with AI

The AI in genomics market is on the cusp of transformative change, driven by rapid technological advancements and significant investment in AI and genomics research. The integration of AI is revolutionizing drug discovery, diagnostics, and personalized medicine, leading to more effective and affordable healthcare solutions. With continued advancements in AI technology and its application in genomics, the future of healthcare is set to be more personalized, efficient, and accessible for patients around the world.

Buy Now  : https://www.meticulousresearch.com/Checkout/40485578

Key Players

The key players operating in the global AI in genomics market are Microsoft Corporation (U.S.), NVIDIA Corporation (U.S.), Deep Genomics Incorporated (Canada), Fabric Genomics, Inc. (U.S.), Data4Cure, Inc. (U.S.), Predictive Oncology Inc. (U.S.), Emedgene Technologies LTD (U.S.), Congenica Ltd. (U.K.), Tempus Labs, Inc. (U.S.), SOPHiA GENETICS SA (Switzerland), Illumina Inc. (U.S.), and BenevolentAI Limited. (U.K.).

Key questions answered in the report-

  • Which are the high-growth market segments in terms of offering, delivery mode, functionality, application, end user, and geography?
  • What was the historical market for AI in genomics across the globe?
  • What are the market forecasts and estimates for the period 2022–2029?
  • What are the major drivers, restraints, opportunities, and challenges in the global AI in genomics market?
  • Who are the major players in the global Artificial Intelligence in genomics market?
  • How is the competitive landscape, and who are the market leaders in the global AI in genomics market?
  • What are the recent developments in the AI in genomics market?
  • What are the different strategies adopted by the major players in the AI in genomics market?
  • What are the geographic trends and high growth regions/countries?

Browse in Depth : https://www.meticulousresearch.com/product/ai-in-genomics-market-5345

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

Comments